Escharotomy Incisions 17

Total Page:16

File Type:pdf, Size:1020Kb

Escharotomy Incisions 17 Emergency War Surgery Second United States Revision of The Emergency War Surgery NATO Handbook Thomas E. Bowen, M.D. Editor BG, MC, U.S. Army Ronald Bellamy, M.D. Co-Editor COL, MC, U.S. Army United States Department of Defense United States Government Printing Office Washington, D.C. 1988 Peer Review Status: Internally Peer Reviewed Creation Date: Unknown Last Revision Date: 1988 Contents Foreword Preface Prologue Acknowledgments Chapter I. General Considerations of Forward Surgery Part I. Types of Wounds and Injuries II. Missile-Caused Wounds III. Burn Injury IV. Cold Injury V. Blast Injuries VI. Chemical Injury VII. Mass Casualties in Thermonuclear Warfare VIII. Multiple Injuries Part II. Response of the Body to Wounding IX. Shock and Resuscitation X. Compensatory and Pathophysiological Responses to Trauma XI. Infection Part III. General Considerations of Wound Management XII. Sorting of Casualties XIII. Aeromedical Evacuation XIV. War Surgery Within the Division XV. Anesthesia and Analgesia XVI. Wounds and Injuries of the Soft Tissues XVII. Crush Injury XVIII. Vascular Injuries XIX. Wounds and Injuries of Bones and Joints XX. Wounds and Injuries of Peripheral Nerves XXI. Amputations Part IV. Regional Wounds and Injuries XXII. Craniocerebral Injury XXIII. Maxillofacial Wounds and Injuries XXIV. Wounds and Injuries of the Eye XXV. Laser Injury of the Eye XXVI. Wounds and Injuries of the Ear XXVII. Wounds and Injuries of the Neck XXVIII. Wounds and Injuries of the Chest XXIX. Wounds of the Abdomen XXX. Reoperative Abdominal Surgery XXXI. Wounds and Injuries of the Genitourinary Tract XXXII. Wounds and Injuries of the Hand XXXIII. Wounds and Injuries of the Spinal Column and Cord Appendixes A. Glossary of Drugs with National Nomenclatures B. Useful Tables Illustrations Figure 1. Generic organization of combat casualty care 2. Wound Profile - Vetterli projectile, circa 1870-1890 3. The sonic shock wave and temporary cavity 4. Wound Profile - .45 Automatic 5. Wound Profile - .22 Long Rifle 6. Wound Profile - .38 Special 7. Wound Profile - 7.62 NATO FMC 8. Wound Profile - AK 47 9. Wound Profile - AK 74 10. Wound Profile - 357 Magnum 11. Wound Profile - 7.62 Soft Point 12. Wound Profile - M-16 M-193 round 13. Wound Profile - .224 Soft Point 14. Wound Profile - 12 gauge shotgun, #4 buckshot 15. Rule of nines for use in determining percentage of burns 16. Sites for escharotomy incisions 17. Pressure-Time representation of an air explosion 18. Human tolerance to blast waves 19. Fallout decay with time after detonation 20. Postradiation syndrome dose and time relationships 21. Proposed scheme for mass casualty flow 22. Casualty care decision tree at the division level 23. A technique for cricothyroidotomy 24. Technique of debridement in soft-tissue wounds 25. External fixation of fractures 26. Immobilization of the upper extremity 27. Technique of open circular amputation 28. Self-contained plaster-incorporated traction device 29. Technique for debridement of head wounds 30. Technique of archbar application to maxillary and mandibular teeth 31. Closure by layers of lid lacerations 32. Technique of tracheostomy 33. Control of bleeding from caval and hepatic vein injuries 34. Drainage of the abdomen 35. Single layer technique for closure of small intestine 36. Exteriorization of colon wounds 37. The end colostomy and matured ileostomy 38. Technique of presacral drainage 39. Immobilization of the injured hand and forearm 40. Sensory Dermatomes 41. Cervical Immobilization using a Short Board 42. Spinal Immobilization using a Long Board 43. Two Man Arm Carry 44. Field Expedient Litter 45. Gardner-Wells Tongs Tables Number 1. Diagnosis of burn depth 2. Formula for estimating fluid requirements in burn patients 3. Chemical warfare agent classification 4. Time of onset with chemical agents 5. Early signs and symptoms of chemical exposure 6. Estimated fluid and blood requirements 7. Choice, mode of action, spectrum, and dosage of antibiotic agents 8. Anatomical distribution of battle wounds 9. Local anesthetic agents 10. Arterial wound and associated injuries, Vietnam, 1965-1970 11. Classification of craniocerebral injuries 12. Mechanism and pathophysiology of craniocerebral injuries 13. Glasgow Coma Scale 14. Typical lasers and their wavelengths 15. Support of the Spinal Column 16. Assessment of Spinal Cord Injuries 17. Extraction techniques for suspected spinal column injuries 18. Application of Gardner-Wells Cranial tongs Foreword United States Department of Defense Peer Review Status: Internally Peer Reviewed The success of any military health care system in wartime is directly related to the number of casualties adequately treated and returned to duty with their units. This must be accomplished as soon and as far forward in the theater of operations as possible. The Second Battle of Bull Run near Manassas, Virginia, was one of the major engagements of the United States Civil War. Three days after that great battle, three thousand wounded men still lay on the field. Relatives traveled to the front and took their loved ones home for treatment rather than leave them to the uncertain ties of military medicine. We have made phenomenal progress in the century since that battle occurred. I have had the privilege of being a physician for nearly forty years. Half of that time was spent on active duty in the military services and the other half was spent in the civilian sector. I have participated in the delivery of health care in every conceivable setting: in a battlefield tent in Korea; on a hospital ship; in an air squadron; from austere county and state hospitals to large, glossy high technology institutions. I have seen people strive for, and achieve, excellence in all those settings. I see it now in the military health care system, and no one is more proud than I of the accomplishments and the quality of that system and of the special type of men and women who make the system work. Our system is not without its problems and its frustrations. It takes a long time for equipment to be delivered; the personnel system doesn't always provide the proper mix of people in a timely manner to get the job done; but with rare exceptions, the medical mission is accomplished in exceptional fashion. This handbook should serve as a constant reminder that ours is a high calling We are here to save lives, not to destroy them. We are committed to the future, not the past, and to the primary mission of military medicine, which is to keep the soldiers, sailors, airmen and marines alive and whole: in the words of Abraham Lincoln, to minister to "him who has borne the brunt of battle." This revised edition represents the contributions of talented and gifted health professionals from the military services as well as from the civilian sector. All who contributed have the grateful appreciation of the editorial board for the enthusiasm, dedication, and perseverance which made this revision possible. William Mayer, MD Assistant Secretary of Defense (Health Affairs) Preface United States Department of Defense Peer Review Status: Internally Peer Reviewed This edition of the Emergency War Surgery Handbook is written for and dedicated to the new generation of young as yet untested surgeons, who may be given the opportunity and the honor of ministering to the needs of their fallen fellow countrymen. What is the likelihood that you will be called to serve? The ancient Plato provided the answer: "Only the dead have seen the end of war!" Will you be adequate, will you be successful in salvaging the lives and limbs of those comrades by applying the principles of the lessons hard learned by countless generations of combat surgeons that have preceded you? The answer is a resounding yes, for "I would remind you how large and various is the experience of the battlefield and how fertile the blood of warriors in the rearing of good surgeons" (T. Clifford Albutt). What sort of wounds will you be expected to manage? The Wound Data and Munitions Effectiveness Team (WDMET) data derived from the Vietnam battlefield provide some insight into the types of wounds and the casualty mix that might be expected. The WDMET data indicate that 100 combat casualties, who survive long enough to be evacuated from the field, could be statistically expected to present the following casualty mix: Thirty casualties with minor or superficial wounds, minor burns, abrasions, foreign bodies in the eye, ruptured ear drums, and deafness. Sixteen with open, comminuted fractures of a long bone, of which several will be multiple and several will be associated with injury of named nerves. Ten with major soft tissue injury or burns requiring general anesthesia for debridement. Several will have injury of named nerves. Ten will require laparotomy, of which two will be negative and several will involve extensive, complicated procedures. Six with open, comminuted fractures of the hand, fingers, feet or toes. Five will require closed thoracostomies and soft tissue wound management; at least one will have a minithoracotomy. Four will have major multiple trauma, i.e., various combinations of craniotomies, thoracotomies, laparotomies, amputations, vascular reconstructions, soft tissue debridements, or fracture management. Three will be major amputations (AK, BK, arm, forearm). In three out of four, the surgeon will simply complete the amputation. Three craniotomies. Two will be craniectomies for fragments and one will involve elevation of a depressed fracture. Three vascular reconstructions, half involving femoral arteries. One half will have associated fractures, or venous or nerve injuries. Three major eye injuries, one of which will require enucleation. Two amputations of hands, fingers, feet or toes. Two maxillofacial reconstructions. Half will have mandibular injuries and most of the remainder will have maxillary injuries. One formal thoracotomy. One neck exploration (usually negative). One casualty statistically is delivered up by the computer as "miscellaneous." If this surgical handbook is on the mark in achieving its objective, we will have provided you with specific guidelines or general principles governing the management of the foregoing 100 randomly selected battle casualties.
Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • Examination of the Spine
    Page 1 of 7 Examination of the Spine Neck and back pain are common presentations in primary care. Many cases of neck and back pain are due to benign functional or postural causes but a thorough history and examination is essential to assess the cause (see articles Low Back Pain and Sciatica, Thoracic Back Pain and Neck Pain), any associated psychological difficulties (eg depression, anxiety or somatisation disorder), and any functional impairment, including restrictions with work, leisure and domestic activities. General examination of the spine The examination should begin as soon as you first see the patient and continues with careful observation during the whole consultation. It is essential to observe the patient's gait and posture. Inconsistency between observed function and performance during specific tests may help to differentiate between physical and functional causes for the patient's symptoms. Inspection Examination of any localised spinal disorder requires inspection of the entire spine. The patient should therefore undress to their underwear. Look for any obvious swellings or surgical scars. Assess for deformity: scoliosis, kyphosis, loss of lumbar lordosis or hyperlordosis of the lumbar spine. Look for shoulder asymmetry and pelvic tilt. Observe the patient walking to assess for any abnormalities of gait. Palpation Palpate for tenderness over bone and soft tissues. Perform an abdominal examination to identify any masses, and consider a rectal examination (cauda equina syndrome may present with low back pain, pain in the legs and unilateral or bilateral lower limb motor and/or sensory abnormality, bowel and/or bladder dysfunction with saddle and perineal anaesthesia, urinary dysfunction and bowel disturbances, and rectal examination may reveal loss of anal tone and sensation).
    [Show full text]
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
    WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
    [Show full text]
  • Harbor Chiropractic, P.C
    American Arbitration Association New York No-Fault Arbitration Tribunal In the Matter of the Arbitration between: Harbor Chiropractic, P.C. AAA Case No. 17-18-1084-8145 (Applicant) Applicant's File No. 113141 - and - Insurer's Claim File No. 0397235870 NAIC No. 19232 Allstate Insurance Company (Respondent) ARBITRATION AWARD I, James Hogan, the undersigned arbitrator, designated by the American Arbitration Association pursuant to the Rules for New York State No-Fault Arbitration, adopted pursuant to regulations promulgated by the Superintendent of Insurance, having been duly sworn, and having heard the proofs and allegations of the parties make the following AWARD: Injured Person(s) hereinafter referred to as: EIP 1. Hearing(s) held on 04/18/2019, 06/19/2019 Declared closed by the arbitrator on 04/18/2019 Michael Spector from The Odierno Law Firm P.C. participated in person for the Applicant Allison Lindsey from Law Offices Of Karen L Lawrence participated in person for the Respondent 2. The amount claimed in the Arbitration Request, $ 4,241.52, was AMENDED and permitted by the arbitrator at the oral hearing. At the hearing, the Applicant amended the amount in controversy to $2,778.45 to be in accordance with the Chiropractic Fee Schedule for both the CMT and physical medicine services provided on the 18 DOS, but also to be in accordance with the fee schedule for the range of motion testing and manual muscle testing. Stipulations WERE NOT made by the parties regarding the issues to be determined. 3. Summary of Issues in Dispute The EIP, a 27 year old female, was injured in a collision on 12/30/15.
    [Show full text]
  • Journal Pre-Proof
    Mayo Clinic Proceedings Telemedicine Musculoskeletal Examination The Telemedicine Musculoskeletal Examination Edward R. Laskowski, MD; Shelby E. Johnson, MD; Randy A. Shelerud, MD; Jason A. Lee, DO; Amy E. Rabatin, MD; Sherilyn W. Driscoll, MD; Brittany J. Moore, MD; Michael C. Wainberg, DO; Carmen M. Terzic, MD, PhD All authors listed are members of the Department of Physical Medicine and Rehabilitation, Mayo Clinic Rochester, and additionally, Dr. Laskowski and Dr. Lee are members of the Division of Sports Medicine of the Department of Orthopedics, Mayo Clinic Rochester. Corresponding Author: Edward R. Laskowski, MD Physical Medicine and Rehabilitation Mayo Clinic 200 First Street SW Rochester, MN 55905 [email protected] Abstract Telemedicine uses modern telecommunication technology to exchange medical information and provide clinical care to individuals at a distance. Initially intended to improve health care to patients in remote settings, telemedicine now has a broad clinical scope with the generalJournal purpose of providing Pre-Proofconvenient, safe, time and cost-efficient care. The Corona Virus Disease 2019 (COVID-19) pandemic has created significant nationwide changes to health care access and delivery. Elective appointments and procedures have been cancelled or delayed, and multiple states still have some degree of shelter-in-place orders. Many institutions are now relying more heavily on telehealth services to continue to provide medical care to individuals while also preserving the © 2020 Mayo Foundation for Medical Education and Research. Mayo Clin Proc. 2020;95(x):xx-xx. Mayo Clinic Proceedings Telemedicine Musculoskeletal Examination safety of healthcare professionals and patients. Telemedicine can also help reduce the surge in health care needs and visits as restrictions are lifted.
    [Show full text]
  • L:\0901 with Peru\0901PHARMAPPX.Wpd
    Harmonized Tariff Schedule of the United States (2009) (Rev. 1) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2009) (Rev. 1) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACEXAMIC ACID 57-08-9 ABAFUNGIN 129639-79-8 ACICLOVIR 59277-89-3 ABAMECTIN 65195-55-3 ACIFRAN 72420-38-3 ABANOQUIL 90402-40-7 ACIPIMOX 51037-30-0 ABAPERIDONE 183849-43-6 ACITAZANOLAST 114607-46-4 ABARELIX 183552-38-7 ACITEMATE 101197-99-3 ABATACEPT 332348-12-6 ACITRETIN 55079-83-9 ABCIXIMAB 143653-53-6 ACIVICIN 42228-92-2 ABECARNIL 111841-85-1 ACLANTATE 39633-62-0 ABETIMUS 167362-48-3 ACLARUBICIN 57576-44-0 ABIRATERONE 154229-19-3 ACLATONIUM NAPADISILATE 55077-30-0 ABITESARTAN 137882-98-5 ACODAZOLE 79152-85-5 ABLUKAST 96566-25-5 ACOLBIFENE 182167-02-8 ABRINEURIN 178535-93-8 ACONIAZIDE 13410-86-1 ABUNIDAZOLE 91017-58-2 ACOTIAMIDE 185106-16-5 ACADESINE 2627-69-2 ACOXATRINE 748-44-7 ACAMPROSATE 77337-76-9 ACREOZAST 123548-56-1 ACAPRAZINE 55485-20-6
    [Show full text]
  • Abstract Acute Emetic Responses to Seven Cancer Chemotherapeutic
    Emesis Induced by Cancer Chemotherapeutic Agents in the Suncus Murinus: A New Experimental Model Norio MATSUKI, Shinya UENO, Takahide KAJI, Akane ISHIHARA, Chao-Hsiung WANG k and Hiroshi SAITO Department of Chemical Pharmacology, Faculty of Pharmaceutical Sciences, University of Tokyo, Tokyo 113, Japan Chia-nan Junior College of Pharmacy, Tainan Hsien, Taiwan Accepted September 1, 1988 Abstract Acute emetic responses to seven cancer chemotherapeutic agents (adriamycin, bleomycin, cisplatin, cyclophosphamide, 5-fluorouracil, methotrexate, mitomycin C) were studied in the Suncus murinus. Intravenous injection of the drugs caused vomiting with various latency. Cisplatin-induced emesis was prevented by the pretreatment with metoclopramide or chlorpromazine but not with domperidone. These results indicate that the Suncus murinus is a useful animal for testing emetic activities of cancer chemotherapeutics and antiemetic activities of prophylactic drugs. Nausea and vomiting, although rarely life threatening, are painful side effects for the patients who receive cancer chemotherapy (1). However, developments of less emetic chemotherapeutic agents and antiemetic drugs are difficult because only a few mammals vomit in response to emetic drugs. The smallest mammal currently available for these purposes is the ferret (2,3), but its body weight is more than 1 kg. If we could use smaller mammals, it would be easier to test various agents for emetic and antiemetic activities. Recently we have shown that the Suncus murinus (house musk shrew), a species of insectivora, vomit in response to various emetic drugs (4) or motion stimulus (5). However, it is not known whether cancer chemotherapeutics induce emesis in the suncus. In the present study emetic response to several chemotherapeutics were investigated in the suncus for its use as a new animal model for emesis testing.
    [Show full text]
  • 1996 Medical Impairment Guidelines
    STATE OF NEW YORK WORKERS' COMPENSATION BOARD MEDICAL GUIDELINES June 1996 David A. Paterson, Governor Robert E. Beloten, Chair TABLE OF CONTENTS FOREWORD ..................................................................................................................................vii INTRODUCTION ............................................................................................................................. 1 A. ROLE OF EXAMINING HEALTH PROVIDERS................................................................ 2 B. ROLE OF THE WORKERS' COMPENSATION LAW JUDGE .......................................... 2 C. DISABILITY EVALUATION IN WORKERS' COMPENSATION CASES. ............... 2 Review of the Claimant's File......................................................................................... 3 1. TYPES OF DISABILITY UNDER THE WORKERS' COMPENSATION LAW ................................................................................................. 3 2. TYPES OF FINAL EVALUATION EXAMINATION .................................................. 3 Schedule Awards ........................................................................................................... 4 Non-Schedule Awards....................................................................................................5 I. EXTREMITIES.............................................................................................................................. 6 A. UPPER EXTREMITIES.........................................................................................................6
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
    Harmonized Tariff Schedule of the United States (2010) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2010) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • List of Psychoactive Drug Spirits for MD A-Methylfentanyl, Abilify
    List of Psychoactive Drug Spirits for MD A-Methylfentanyl, Abilify, abnormal basal ganglia function, abuse of medicines, Aceperone, Acepromazine, Aceprometazine, Acetildenafil, Aceto phenazine, Acetoxy Dipt, Acetyl morphone, Acetyl propionyl morphine, Acetyl psilocin, Activation syndrome, acute anxiety, acute hypertension, acute panic attacks, Adderall, Addictions to drugs, Addictions to medicines, Addictions to substances, Adrenorphin, Adverse effects of psychoactive drugs, adverse reactions to medicines, aggression, aggressive, aggressiveness, agitated depression, Agitation and restlessness, Aildenafil, Akuammine, alcohol abuse, alcohol addiction, alcohol withdrawl, alcohol-related brain damage, alcohol- related liver damage, alcohol mix with medicines for adverse reaction, Alcoholism, Alfetamine, Alimemazine, Alizapride, Alkyl nitrites, allergic breathing reactions to meds, choking to anaphallectic shock, & death; allergic skin reactions to meds, rash, itchyness, hives, welts, etc, Alletorphine, Almorexant, Alnespirone, Alpha Ethyltryptamine, Alpha Neoendorphin, alterations in brain hormones, alterations in mental status, altered consciousness, altered mind, Altoqualine, Alvimopan, Ambien, Amidephrine, Amidorphin, Amiflamine, Amisulpride, Amphetamines, Amyl nitrite, Anafranil, Analeptic, Anastrozole, Anazocine, Anilopam, Antabuse, anti anxiety meds, anti dopaminergic activity, anti seizure meds, Anti convulsants, Anti depressants, Anti emetics, Anti histamines, anti manic meds, anti parkinsonics, Anti psychotics, Anxiety disorders,
    [Show full text]
  • Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes
    Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABACAVIR 136470-78-5 ACEXAMIC ACID 57-08-9 ABAFUNGIN 129639-79-8 ACICLOVIR 59277-89-3 ABAMECTIN 65195-55-3 ACIFRAN 72420-38-3 ABANOQUIL 90402-40-7 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABIRATERONE 154229-19-3 ACIVICIN 42228-92-2 ABITESARTAN 137882-98-5 ACLANTATE 39633-62-0 ABLUKAST 96566-25-5 ACLARUBICIN 57576-44-0 ABUNIDAZOLE 91017-58-2 ACLATONIUM NAPADISILATE 55077-30-0 ACADESINE 2627-69-2 ACODAZOLE 79152-85-5 ACAMPROSATE 77337-76-9 ACONIAZIDE 13410-86-1 ACAPRAZINE 55485-20-6 ACOXATRINE 748-44-7 ACARBOSE 56180-94-0 ACREOZAST 123548-56-1 ACEBROCHOL 514-50-1 ACRIDOREX 47487-22-9 ACEBURIC ACID 26976-72-7
    [Show full text]